Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11361195 | 0.87 | KMT2A (0.40) | KMT2ATSHRPTGS1PTGS2HDAC4 | |
| SCHEMBL1968557 | 0.83 | TDP1 (0.42) | KMT2AHPGDLMNA | |
| SCHEMBL497246 | 0.83 | BRD4 (0.43) | HPGDCYP2D6HDAC4HDAC7HDAC5 | |
| SCHEMBL268626 | 0.83 | TDP1 (0.42) | KMT2AHPGDLMNA | |
| SCHEMBL27533616 | 0.81 | KMT2A (0.47) | KMT2ATSHRPTGS1PTGS2HPGD | |
| SCHEMBL270922 | 0.81 | HDAC3 (0.42) | KMT2ATSHRLMNACYP2D6CYP3A4 | |
| SCHEMBL496445 | 0.81 | RAB9A (0.46) | KMT2ATSHRPTGS1PTGS2CES2 | |
| SCHEMBL923969 | 0.81 | CYP1A2 (0.46) | KMT2AHPGDLMNACYP1A2MAPK1 | |
| SCHEMBL270288 | 0.81 | CYP2C19 (0.42) | LMNACYP2D6CYP3A4MAPK1HSD17B10 | |
| SCHEMBL271270 | 0.81 | HPGD (0.41) | KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3676261-B1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LTD (GB) | 2024-12-18 | — | — | EP | disclosed |
| CN-111315734-B | Substituted 2-azabicyclo [3.1.1] heptane and 2-azabicyclo [3.2.1] octane derivatives as orexin receptor antagonists | 克罗诺斯治疗有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | CHRONOS THERAPEUTICS LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-20220331299-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LIMITED (GB) | 2022-10-20 | — | — | US | disclosed |
| EP-3676261-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Chronos Therapeutics Limited (GB) | 2020-07-08 | — | — | EP | disclosed |
| CN-111315734-A | Substituted 2-azabicyclo [3.1.1] heptane and 2-azabicyclo [3.2.1] octane derivatives as orexin receptor antagonists | 克罗诺斯治疗有限公司 | 2020-06-19 | — | — | CN | disclosed |
| WO-2019043407-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LIMITED (GB) | 2019-03-07 | — | — | WO | disclosed |
| US-20180125848-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2018-05-10 | — | — | US | disclosed |
| US-9833455-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | SPACEFILL ENTERPRISES LLC (US) | 2017-12-05 | — | — | US | disclosed |
| EP-2318367-B1 | PIPERIDINE AND PYRROLIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-03-20 | — | — | EP | disclosed |
| WO-2009022311-A2 | 1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009016560-A2 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016564-A2 | 2-AZA-BICYCLO[3.3.0]OCTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009004584-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008139416-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008117241-A2 | THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008081399-A2 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-10 | — | — | WO | disclosed |
| US-4298375-A | REDUCTION OF HERBICIDAL INJURY TO SORGHUM PLANTS | MONSANTO COMPANY (US) | 1981-11-03 | — | — | US | disclosed |
| US-4275200-A | CONDENSATION OF CARBAMIC ESTERS WITH X-HALOGEN CARBONYL COMPOUNDS | AGFA-GEVAERT, A.G. (DE) | 1981-06-23 | — | — | US | disclosed |
| US-4059447-A | Photographic material containing oxazolinone-2 couplers | AGFA-GEVAERT AKTIENGESELLSCHAFT (DT) | 1977-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125848-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | KMT2A 720/4885TSHR 1513/4885PTGS1 4293/4885 |
| US-20220331299-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | KMT2A 1082/4885TSHR 158/4885PTGS1 3099/4885 |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, NPY1R | KMT2A 1082/4885TSHR 158/4885PTGS1 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.